Clinical trial
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally…
NCT00019682 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019682 |
|---|---|
| Title | Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma |
| Official title | A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma |
| Intervention type | Biological, Drug, Other |
| Interventions | Aldesleukin, gp100 Antigen, Montanide ISA 51 VG, Quality-of-Life Assessment, Questionnaire Administration, Laboratory Biomarker Analysis |
| Enrollment | 185 |
| Start date | Dec 1, 1999 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 20, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: